A Phase 1, Multi-Center, Open-Label Study to Assess Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BAT6021 as Mono Therapy or in Combination With Tislelizumab in Patients With Advanced Solid Tumors
Latest Information Update: 13 Oct 2023
At a glance
- Drugs BAT 6021 (Primary) ; Tislelizumab
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Bio-Thera Solutions
- 08 Oct 2023 Status changed from recruiting to discontinued.
- 26 Jul 2022 Planned primary completion date changed from 1 Nov 2022 to 1 Jun 2023.
- 26 Jul 2022 Status changed from not yet recruiting to recruiting.